Lupus & antiphospholipid syndrome
Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis
Authors' conclusion
These findings uncovered the predictors of Ld-IL2 treatment efficacy in SLE patients and provided guidance to physicians for rational utilization.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients undergoing sequential low-dose IL-2 treatment314 persisting >3 months analysed
- Participants
- 342 patients
- Exposure
- SRI-4 responders vs non-responders to low-dose IL-2
- Respondern = 136
- Non-respondern = 178reference
- Outcome
- Predictors of achieving SRI-4 response
Methodological detailspooled real-world data, prediction analysis
- Pooled real-world data
- Prediction analysis
Main finding
As reported in the abstract
Prediction of SRI-4 response
AUC of rash, renal involvement, % change of CD4+ T cells and C3 for predicting SRI-4
0.933
Observational data: associations, not effects.
Further findings
Prediction of Lupus Low Disease Activity State (LLDAS) attainment
- Hematological involvement and lower CLA+ Treg were potent predictive markers of LLDAS attainment
- Renal involvement not significantly associated with achieving LLDAS
Background therapy
- MMF more likely to reach SRI-4 response in combination with Ld-IL2
Original publication
Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis. Arthritis Res Ther. Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →